Dr. Shah on the Safety of a Novel Dual-Targeted CAR T-Cell Therapy in Non-Hodgkin Lymphoma

Video

Nirav Shah, MD, MCW, discusses the safety profile of an anti-CD20/anti-CD19 CAR T-cell therapy under investigation in the treatment of patients with non-Hodgkin lymphoma.

Nirav Shah, MD, MCW, an associate professor at the Medical College of Wisconsin, discusses the safety profile of an anti-CD20/anti-CD19 CAR T-cell therapy under investigation in the treatment of patients with non-Hodgkin lymphoma.

The safety of the CAR T-cell product was examined in a phase 1 study that launched in 2017, according to Shah. When the trial began, it was one of the first studies to examine a dual-targeted agent in this patient population. Because of this, it was very important to demonstrate the product's safety, Shah explains, as there are concerns that targeting more than 1 B-cell antigen could result in increased toxicities like cytokine release syndrome (CRS) and neurotoxicity.

The CAR T-cell therapy was found to be safe, Shah says. The incidence of CRS and neurotoxicity were low and no patients died as a result of undergoing treatment. Additionally, the adverse effects reported in patients were found to be reversible. Investigators were able to identify a safe and efficacious dose of 2.5 × 106 cells/kg that will be further evaluated in a larger phase 2 study. With this effort, investigators hope to further demonstrate the efficacy of the product.

Although the agent has already shown a promising response signal, the phase 1 study was comprised of a smaller patient population, Shah explains. The phase 2 study will offer the opportunity to evaluate the recommended phase 2 dose of the agent in a larger patient population, Shah concludes.

Recent Videos
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Related Content
© 2025 MJH Life Sciences

All rights reserved.